BioNTech SE
BNTXNasdaqCIK 1776985HealthcareFiscal year ends Dec 31
Revenue is not reported in this company’s XBRL financial statements.
Latest quarter: not reported
Last eight quarters
Full statements| Line item | Unit | Shape over the periods |
|---|---|---|
| Revenue | $ | |
| Gross margin | % | |
| Operating margin | % | |
| Net margin | % | |
| Diluted EPS | $ per share | |
| Free cash flow | $ |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Last five fiscal years
| Line item | Unit | FY20212021-12-31 | FY20222022-12-31 | FY20232023-12-31 | FY20242024-12-31 | FY20252025-12-31 | Shape over the periods |
|---|---|---|---|---|---|---|---|
| Revenue | $bn | 19.0Revenue, FY2021, twelve months to 2021-12-31EUR 18.98bn. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2024-03-20, accession 0001776985-24-000027.Report this figure | 17.3Revenue, FY2022, twelve months to 2022-12-31EUR 17.31bn. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2025-03-10, accession 0001776985-25-000013.Report this figure | 3.8Revenue, FY2023, twelve months to 2023-12-31EUR 3.82bn. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2026-03-10, accession 0001776985-26-000017.Report this figure | 2.8Revenue, FY2024, twelve months to 2024-12-31EUR 2.75bn. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2026-03-10, accession 0001776985-26-000017.Report this figure | 2.9Revenue, FY2025, twelve months to 2025-12-31EUR 2.87bn. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2026-03-10, accession 0001776985-26-000017.Report this figure | |
| Gross margin | % | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | |
| Operating margin | % | 80.5%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: EUR 15.28bn. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2024-03-20, accession 0001776985-24-000027.Revenue: EUR 18.98bn. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2024-03-20, accession 0001776985-24-000027.Report this figure | 73.0%Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: EUR 12.64bn. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2025-03-10, accession 0001776985-25-000013.Revenue: EUR 17.31bn. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2025-03-10, accession 0001776985-25-000013.Report this figure | 18.1%Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: EUR 690.4m. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2026-03-10, accession 0001776985-26-000017.Revenue: EUR 3.82bn. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2026-03-10, accession 0001776985-26-000017.Report this figure | (47.8%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −EUR 1.31bn. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2026-03-10, accession 0001776985-26-000017.Revenue: EUR 2.75bn. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2026-03-10, accession 0001776985-26-000017.Report this figure | (49.0%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −EUR 1.40bn. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2026-03-10, accession 0001776985-26-000017.Revenue: EUR 2.87bn. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2026-03-10, accession 0001776985-26-000017.Report this figure | |
| Net margin | % | 54.2%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: EUR 10.29bn. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2024-03-20, accession 0001776985-24-000027.Revenue: EUR 18.98bn. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2024-03-20, accession 0001776985-24-000027.Report this figure | 54.5%Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: EUR 9.43bn. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2025-03-10, accession 0001776985-25-000013.Revenue: EUR 17.31bn. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2025-03-10, accession 0001776985-25-000013.Report this figure | 24.4%Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: EUR 930.3m. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2026-03-10, accession 0001776985-26-000017.Revenue: EUR 3.82bn. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2026-03-10, accession 0001776985-26-000017.Report this figure | (24.2%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −EUR 665.3m. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2026-03-10, accession 0001776985-26-000017.Revenue: EUR 2.75bn. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2026-03-10, accession 0001776985-26-000017.Report this figure | (39.6%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −EUR 1.14bn. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2026-03-10, accession 0001776985-26-000017.Revenue: EUR 2.87bn. XBRL concept ifrs-full:RevenueFromContractsWithCustomers. 20-F filed 2026-03-10, accession 0001776985-26-000017.Report this figure | |
| Diluted EPS | $ per share | 39.63Diluted EPS, FY2021, twelve months to 2021-12-31EUR 39.63 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2024-03-20, accession 0001776985-24-000027.Report this figure | 37.77Diluted EPS, FY2022, twelve months to 2022-12-31EUR 37.77 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2025-03-10, accession 0001776985-25-000013.Report this figure | 3.83Diluted EPS, FY2023, twelve months to 2023-12-31EUR 3.83 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2026-03-10, accession 0001776985-26-000017.Report this figure | (2.77)Diluted EPS, FY2024, twelve months to 2024-12-31−EUR 2.77 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2026-03-10, accession 0001776985-26-000017.Report this figure | (4.70)Diluted EPS, FY2025, twelve months to 2025-12-31−EUR 4.70 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2026-03-10, accession 0001776985-26-000017.Report this figure | |
| Free cash flow | $bn | 0.8Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: EUR 889.7m. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2024-03-20, accession 0001776985-24-000027.Capital expenditure: EUR 127.5m. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2024-03-20, accession 0001776985-24-000027.Report this figure | 13.2Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: EUR 13.58bn. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2025-03-10, accession 0001776985-25-000013.Capital expenditure: EUR 329.2m. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2025-03-10, accession 0001776985-25-000013.Report this figure | 5.1Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: EUR 5.37bn. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2026-03-10, accession 0001776985-26-000017.Capital expenditure: EUR 249.4m. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2026-03-10, accession 0001776985-26-000017.Report this figure | (0.1)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: EUR 207.7m. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2026-03-10, accession 0001776985-26-000017.Capital expenditure: EUR 286.5m. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2026-03-10, accession 0001776985-26-000017.Report this figure | 0.3Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: EUR 456.0m. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2026-03-10, accession 0001776985-26-000017.Capital expenditure: EUR 175.1m. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2026-03-10, accession 0001776985-26-000017.Report this figure |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Insider purchases and sales
All insider transactionsThe last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.
No open-market purchases or sales by insiders are in coverage from Dec 2024 to Nov 2026.
No open-market purchases or sales by insiders are in coverage for this company.
Funds that report holding it
All fundsFrom each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.
| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|
| FMR LLC | 2026-06-30 | $704.6m | 7,571,805 | Added+1,862,565 | |
| PRIMECAP MANAGEMENT CO/CA/ | 2026-06-30 | $351.0m | 3,772,031 | Reduced−21,680 | |
| Dodge & Cox | 2026-06-30 | $342.2m | 3,677,591 | Added+800 | |
| FLOSSBACH VON STORCH SE | 2026-06-30 | $207.1m | 2,226,138 | Reduced−1,454,177 | |
| BlackRock, Inc. | 2026-06-30 | $172.6m | 1,854,966 | Added+196,813 | |
| Temasek Holdings (Private) Ltd | 2026-06-30 | $140.1m | 1,506,027 | Unchanged | |
| BNP PARIBAS FINANCIAL MARKETS | 2026-06-30 | $122.8m | 1,319,517 | Reduced−332,272 | |
| Logos Global Management LP | 2026-06-30 | $94.4m | 1,015,000 | New+1,015,000 | |
| GSK plc | 2026-06-30 | $82.8m | 889,824 | Unchanged | |
| FIRST TRUST ADVISORS LP | 2026-06-30 | $73.6m | 791,469 | Reduced−48,522 |
Recent filings
All 585 filingsReports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2606:23 ET | 6-K | Report of a foreign private issuerPeriod 2026-10-26 | 0001776985-26-000074 |
| 2026-10-2207:49 ET | 6-K | Report of a foreign private issuerPeriod 2026-10-22 | 0001776985-26-000072 |
| 2026-10-1907:26 ET | 6-K | Report of a foreign private issuerPeriod 2026-10-19 | 0001776985-26-000069 |
| 2026-10-1316:08 ET | 6-K | Report of a foreign private issuerPeriod 2026-10-13 | 0001776985-26-000067 |
| 2026-09-1816:09 ET | 6-K | Report of a foreign private issuerPeriod 2026-09-18 | 0001776985-26-000065 |
| 2026-09-1408:28 ET | 6-K | Report of a foreign private issuerPeriod 2026-09-14 | 0001776985-26-000063 |
| 2026-08-2809:06 ET | 6-K | Report of a foreign private issuerPeriod 2026-08-28 | 0001776985-26-000061 |
| 2026-08-2716:54 ET | 6-K | Report of a foreign private issuerPeriod 2026-08-27 | 0001776985-26-000059 |
| 2026-08-2007:36 ET | 6-K | Report of a foreign private issuerPeriod 2026-08-20 | 0001776985-26-000057 |
| 2026-08-0407:01 ET | 6-K | Report of a foreign private issuerPeriod 2026-06-30 | 0001776985-26-000055 |
Latest annual report
Form 20-F for the fiscal year ended Dec 31, 2025Filed Mar 10, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.
Forecast league
Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league
About the filer
- CIK
- 1776985
- Tickers
- BNTX
- Exchange
- Nasdaq
- SIC code
- 2836 Biological Products, (No Diagnostic Substances)
- Sector
- Healthcare
- Fiscal year ends
- Dec 31
- Incorporated in
- 2M
- Filer category
- Large accelerated filer
Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 06:48 ET. Listed shows no prices and gives no investment advice.